Antares Pharma Inc

Antares Pharma — Investor Presentation (May 2006)

19 slides from Antares Pharma's investor presentation, May 5, 2006

  1. Slide 1: Analysts & Investors Presentation: Antares Pharma – Devices Group

    1 st Analysts & Investors Presentation Antares Pharma – Devices Group Exhibit 99.2

  2. Slide 2: Safe Harbor Statement

    Antares Pharma, Inc. © 2006 Confidential This presentation may contain forward-looking statements which are made pursuant to the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Investors are cautioned that stateme

  3. Slide 3: Antares' Devices Group History

    Antares Pharma, Inc. © 2006 Confidential Medi-Ject Corporation (1979-2001) Pioneered needle-free injection technology for insulin First pharma partnership…a needle-free pharmaceutical product Medi-Ject and Permatec merger Combining pharma and device technology Leading the pharma industry trend of dr

  4. Slide 4: Key Market Segments – Injection Devices

    Antares Pharma, Inc. © 2006 Confidential Key Market Segments – Injection Devices Multi-Dose / Variable-Dose Injectors Single-Dose / Fixed-Dose Injectors Pre-Filled Syringes & Safety Syringes Mini-Needle & Hybrid Devices Antares Pharma Mini-Needle & Hybrid Devices Antares Pharma Auto-Injectors •Medic

  5. Slide 5: Injection Device Platforms

    Antares Pharma, Inc. © 2006 Confidential Antares’ Injection Device Platforms Core technology is “Pressure Assisted Delivery” Evolution from Needle-Free to Mini-Needle to Hybrid devices Core Technology Pressure assisted delivery Minimally invasive injection Customer Defined Product Opportunities Anta

  6. Slide 6: Needle-Free Category

    Antares Pharma, Inc. © 2006 Confidential Needle-Free Category Antares is a winner…but adoption has been slow Opportunity exists, but requires pharma participation Greystone forecasts growth from $10.2M in 2002 to $425M in 2007!! Critical Success Factors: 1. Viable technology 2. Customer solution 3.

  7. Slide 7: Strong Intellectual Property

    Antares Pharma, Inc. © 2006 Confidential Strong Intellectual Property Intellectual property is key to out-licensing Protection of device technology Core technology—a blocking strategy Mini-needle strategy Freedom to operate User interfaces and unique mechanisms Commercialization Protect specific or

  8. Slide 8: Value Proposition: Patient and Pharma Partner Benefits

    Antares Pharma, Inc. © 2006 Confidential Patient Benefits Perceived comfort Ease-of-use Safety No sharps Depth of delivery Pharma Partner Benefits Maintain existing filling process and primary drug container Patents / IP Experienced, successful device designer/developer Differentiated products Value

  9. Slide 9: The Time is Right for Injection Devices

    Antares Pharma, Inc. © 2006 Confidential Growing need for delivery of proteins Bio-generics are coming New biotech, large molecules Convergence of drugs & devices into products Need for product differentiation Branded/innovator products and super-generics Movement to outpatient treatment Driven by r

  10. Slide 10: The hGH Story

    Antares Pharma, Inc. © 2006 Confidential hGH the first biogeneric Ferring (Europe) – Zomajet VISION2® Compelling point of difference resulting in market share Growth opportunities – new markets/expansion JCR Pharmaceuticals (Japan) - Twin-Jector® EZ-II Kyoto product re-launch driven by new device Co

  11. Slide 11: Pipeline Opportunities

    Antares Pharma, Inc. © 2006 Confidential Interferons Hepatitis $2.5B in 2004 Maxygen, Inc. 2005 MS $4.4B in 2004 Wood Mackenzie ProductView™, 2005 Oncology/hematology blood cell factors (Epogen, Procrit, Neupogen etc.) $16.1B in 2005 S. G. Cowen & Co., 2006 Biogenerics $2.2B forecast for 2010 Pharma

  12. Slide 12: Hybrid Platform Development

    Antares Pharma, Inc. © 2006 Confidential Hybrid Platform Development Dual chamber injector • Reconstitutes drug prior to injection Variable dose injector •Variable dosing from unit dose containers Microdose injector • Intradermal and small volume SC delivery Providing Mini-Needle platform based solu

  13. Slide 13: Hybrid Benefits

    Antares Pharma, Inc. © 2006 Confidential Hybrid Benefits Benefits Shortens timelines Solving formulation challenges Decreases capital investment Simplified or improved product performance Examples Reconstitution device … avoids reformulation Microdose device … for intradermal injection, minimizes te

  14. Slide 14: TEVA Agreement

    Antares Pharma, Inc. © 2006 Confidential TEVA Agreement Program is in commercialization stage Development is progressing on schedule Strengths of both companies are reflected in the program progress Validates Antares technology … technical aspects and value proposition Cornerstone program for TEVA …

  15. Slide 15: Lilly Agreement

    Antares Pharma, Inc. © 2006 Confidential Lilly Agreement Program update Needle-free at design freeze and patent filing stage Diabetes and obesity opportunity is growing—and very dynamic Pharmaceutical products in category are mostly drug-device Exubera® launch—delivery is important Increase in insul

  16. Slide 16: Bioterrorism Initiatives

    Antares Pharma, Inc. © 2006 Confidential Bioterrorism Initiatives Opportunity—multiple end users Military, public health & general public Auto-injectors in use today Antares’ technology applicable Initiatives Follow up on technology inquiries Use consultants to help navigate government opportunities

  17. Slide 17: Business Model

    Antares Pharma, Inc. © 2006 Confidential Develop prototype product based on core technology Target right device for right partner and product opportunity Partners fund development to commercialization via milestones License in narrow field of use Antares controls manufacturing Revenue from transfer

  18. Slide 18: Summary

    Antares Pharma, Inc. © 2006 Confidential Summary Market is changing Growth in injectable drug category Increased need for product differentiation Right technology base Differentiated products protected by strong IP New cutting edge products Successful pharma partnerships Business model that works Fo

  19. Slide 19: Me> antares

    Me> antares pharma

Antares Pharma — Investor Presentation (May 2006) on 6ix